KRAS and neoplasm: Preclinical studies exploring the response of tumors to KRAS G12C inhibitors using spatial and multi-omic technologies have highlighted the role of particular populations of immune cells in the TME in impeding immune attack on the tumor, pointing the way to novel approaches to combining RAS inhibition with immunotherapies.